Hirsutism

Reading File

Finding Sources

Searching PubMed

hirsutism management treatment

Reading File

Loading Image

Here is a thorough overview of hirsutism drawn from Harrison's, Fitzpatrick's, Family Medicine, and Goodman & Gilman's.

Hirsutism

Definition

Hirsutism is the presence of excess terminal (coarse, pigmented) hair in women growing in a male-pattern distribution - affecting androgen-sensitive areas such as the upper lip, chin, cheeks, chest, lower abdomen, inner thighs, and back. It is distinct from hypertrichosis, which is a generalized increase in fine vellus hair that is androgen-independent (associated with hypothyroidism, anorexia nervosa, or drugs like minoxidil, diazoxide, diphenylhydantoin).

Prevalence: ~5-15% of women of reproductive age.

Pathogenesis

The hair follicle cycle has three phases: anagen (growth), catagen (involution), and telogen (rest). Androgens drive conversion of vellus hair into terminal hair by activating androgen receptors in the follicle.

Testosterone and DHT are the key androgens. DHT is the most potent - formed locally within the hair follicle by 5α-reductase acting on testosterone.
DHT binds nuclear androgen receptors, activating genes that convert vellus to terminal hair in androgen-sensitive regions.
Androgens are produced by the ovaries (under LH control) and adrenal glands (under ACTH), with additional peripheral conversion.

Two main drivers:

Elevated circulating androgens (most common)
Increased end-organ sensitivity to normal androgen levels (idiopathic hirsutism) - due to upregulated 5α-reductase activity or intrinsic androgen receptor hyperresponsiveness

Causes

Etiology	Key Features
Idiopathic hirsutism (IH)	Regular ovulation, normal/slightly elevated androgens; diagnosis of exclusion; prevalence 4-7%
PCOS (most common secondary cause)	Chronic anovulation, insulin resistance, infertility; >50% present with hirsutism, often truncal
Non-classical CAH (21-hydroxylase deficiency)	Late-onset; elevated 17-hydroxyprogesterone
HAIR-AN syndrome	Hyperandrogenism + Insulin Resistance + Acanthosis Nigricans; 1-5% of hyperandrogenic women
Androgen-secreting tumors	Ovarian or adrenal; rapid/abrupt onset is a red flag for malignancy
Ovarian hyperthecosis	Severe hyperandrogenism; nests of luteinized theca cells in ovarian stroma
Hyperprolactinemia	Via stimulation of adrenal androgens
Exogenous androgens	Anabolic steroids, danazol, some progestins
Cushing syndrome	Cortisol excess with adrenal androgen co-production

Assessment: Modified Ferriman-Gallwey (mFG) Score

The mFG score is the standard assessment tool. Nine body areas are each scored 0 (no hair) to 4 (frankly virile):

Modified Ferriman-Gallwey scoring scale showing hair density at 9 body sites rated 1-4

The nine areas: upper lip, chin/cheeks, chest, upper abdomen, lower abdomen, upper arm, inner thigh, upper back, lower back.

Score	Interpretation
≤8	Normal
8-14	Mild hirsutism
≥15	Moderate to severe hirsutism

Important: Ethnic variation matters - Asian women have lower baseline hair density, Mediterranean women naturally have higher scores. Normal ethnic variation must be distinguished from pathologic hyperandrogenism.

Clinical Evaluation

History: Age of onset, menstrual irregularity, rate of progression (rapid onset = malignancy concern), medications/supplements, family history, ethnic background.

Signs of virilization (suggests significant androgen excess - investigate aggressively):

Clitoromegaly
Male-pattern balding
Voice deepening
Decreased breast size

Other cutaneous signs of hyperandrogenism: Acne, acanthosis nigricans, androgenetic alopecia, seborrheic dermatitis.

When to test hormones:

Mild hirsutism + regular cycles: Likely idiopathic; hormone testing not mandatory
Moderate-severe hirsutism OR any hirsutism + irregular cycles OR virilization: Mandatory hormone workup

Laboratory workup:

Total and bioavailable testosterone
DHEA-S (adrenal androgen marker)
17-hydroxyprogesterone (to rule out non-classical CAH)
Prolactin (if suspected hyperprolactinemia)
24-hour urine 17-ketosteroids (if adrenal tumor suspected)
Imaging: pelvic ultrasound (ovarian cysts/masses), CT/MRI (adrenal masses)

Treatment

Non-pharmacologic (for all patients, alone or as adjunct)

Method	Notes
Shaving	Does NOT increase hair rate or density (common misconception)
Chemical depilatory creams	Useful for mild/limited areas; may cause irritation
Waxing/plucking	Temporary removal; waxing is uncomfortable
Electrolysis	Effective for permanent removal of small areas
Laser / Intense Pulsed Light (IPL)	Best for large areas of pigmented terminal hair; selective photothermolysis via melanin absorption; permanent in many patients

Recent 2024 systematic review (PMID 38630483, JAMA Dermatol) supports laser and light-based therapies for hirsutism in PCOS women.

Pharmacologic

Response is typically not visible for 4-6 months; maximum effect may take 9-12 months (due to the hair growth cycle length).

1. Combined oral contraceptive pills (first-line)

Suppress LH → reduce ovarian androgen production
Increase SHBG → reduce free testosterone
Direct suppressive effect on sebaceous glands
~20% improvement in hirsutism; ~50% improvement in acne
Progestin choice matters: Prefer drospirenone (anti-androgenic, spironolactone analogue) or norgestimate (non-androgenic); avoid norgestrel/levonorgestrel (androgenic)
Contraindicated in thromboembolic disease, estrogen-dependent cancers; relative CI in smokers, hypertension, migraine

2. Spironolactone (100-200 mg/day)

Mineralocorticoid antagonist + weak antiandrogen (competitive androgen receptor inhibitor)
Nearly as effective as cyproterone acetate at adequate doses
Monitor: hyperkalemia, hypotension
Must avoid pregnancy (risk of feminization of male fetus)
Often combined with OCP to regularize cycles and prevent pregnancy

3. Cyproterone acetate (50-100 mg days 1-15)

Prototypic antiandrogen - competitive inhibitor of testosterone and DHT binding to androgen receptor
Also enhances hepatic clearance of testosterone
Combined with ethinyl estradiol (50 μg days 5-26)
Not available in the US, but widely used in Canada, Mexico, Europe
Side effects: irregular bleeding, nausea, headache, fatigue, weight gain, decreased libido

4. Finasteride

Competitive inhibitor of 5α-reductase type 2
Limited efficacy in hirsutism (type 1 predominates in pilosebaceous unit)
Avoid in women who may become pregnant (male fetal feminization risk)
Dutasteride (inhibits both 5α-reductase types 1 and 2) may have better efficacy; evidence growing

5. Flutamide

Potent nonsteroidal antiandrogen; effective but rarely used
Risk of hepatocellular toxicity limits use

6. Glucocorticoids

Used specifically for CAH-related hirsutism
OCPs preferred first-line even in CAH; glucocorticoids added if OCP response is inadequate
Use lowest effective dose (e.g., dexamethasone 0.2-0.25 mg/day at bedtime)

7. Topical eflornithine

Inhibits ornithine decarboxylase in hair follicles → slows growth
Facial hirsutism; used as adjunct to laser/IPL

8. Metformin / insulin sensitizers

Used when hirsutism is driven by insulin resistance (PCOS)
A 2026 systematic review (PMID 41277478, Clin Endocrinol) supports short-term low-dose spironolactone for PCOS-related hyperandrogenism

Summary Algorithm

Hirsutism
    |
    ├── Mild + regular cycles → mFG score, cosmetic treatment, OCP if desired
    |
    ├── Moderate-severe OR irregular cycles → Full hormone workup
    |        ↓
    |   Elevated T (>200 ng/dL) or DHEA-S (>700 µg/dL) → Imaging for tumor
    |   17-OHP elevated → Non-classical CAH
    |   PCOS criteria → OCP ± spironolactone + lifestyle
    |
    └── Virilization → Urgent evaluation, rule out androgen-secreting tumor

Sources: Harrison's Principles of Internal Medicine 22E, p. 3184-3185 | Fitzpatrick's Dermatology Vol. 1-2, pp. 1585-1590 | Textbook of Family Medicine 9e, p. 1053 | Goodman & Gilman's Pharmacological Basis of Therapeutics

This is a shared conversation. Sign in to Orris to start your own chat.